The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities. The study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .
Controlled study, testing a structured implementation of an appropriate management of elderly AF patients with multimorbidity in clinical practice (adapting the ABC pathway and integrating the means of CGA) versus usual care; it is designed to provide reliable evidence of an active holistic integrated management approach to a common, multimorbid and 'high risk' clinical condition. AFFIRMO use a novel platform (iABC) in a cluster randomized trial design, randomizing centres to iABC versus usual care. Centres will be selected in each participating country (Bulgaria, Denmark, Italy, Romania, Serbia and Spain) under the responsibility of National Coordinators on the basis of a demonstrated interest in managing patients with AF. The 8-10 participating clusters in each country (see study size below) will be randomized in a 1:1 ratio to receive a quality-improvement intervention (iABC, experimental group) or 'usual care' practice (control group). The randomization will occur in each Country once all clusters selected in the Country have obtained IRB approval. The allocation schedule for random assignment of care models (iABC or usual care) to sites will be computer generated at the Central Coordinating Centre. The clusters in each Country will be stratified in 2 groups: Centres with or without interventional electrophysiology laboratory for AF ablation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,250
The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
MHAT Haskovo AD-Cardiology
Haskovo, Bulgaria
RECRUITINGSHATS Sveti Georgi - Pernik-Cardiology
Pernik, Bulgaria
RECRUITINGMBAL Sv. Ivan Rilski-Cardiology
Plovdiv, Bulgaria
RECRUITINGUMBAL Sveti Georgi EAD-Clinic of Cardiology
Plovdiv, Bulgaria
Impact of iABC on all cause unplanned hospitalization
All-cause unplanned hospitalization
Time frame: 12 months
Impact of iABC on the composite endpoint of non ischemic stroke, transient ischemic attack and cardiovascular death
A 'composite endpoint' of nonfatal ischemic stroke, transient ischemic attack, and cardiovascular death
Time frame: 12 months
Impact of iABC on secondary outcome measures
all-cause mortality
Time frame: 12 months
Impact of iABC on secondary outcome measures
all-cause mortality and all-cause (planned and unplanned) hospitalizations
Time frame: 12 months
Impact of iABC on secondary outcome measures
new diagnosis of HF or worsening HF requiring hospitalizations
Time frame: 12 months
Impact of iABC on secondary outcome measures
quality of life assessed with EQ-5D-5L questionnaire
Time frame: 12 months
Impact of iABC on secondary outcome measures
major bleeds defined according to the ISTH definitions
Time frame: 12 months
Impact of iABC on secondary outcome measures
intracranial bleeds
Time frame: 12 months
Impact of iABC on secondary outcome measures
occurrence of renal dysfunction or worsening renal function
Time frame: 12 months
Level of adherence to iABC pathway
Level of adherence to iABC pathway will be evaluated by: * the number of accesses to the APP. * daily patient's adherence to oral anticoagulant therapy, * weekly blood pressure and weight self-measurements input * weekly AF symptoms related questionnaires completion
Time frame: 12 months
Impact of iABC on self reported physical activity
Impact of iABC on self reported physical activity
Time frame: 12 months
Level of empowerment and engagement of patient assessed with PHE-S questionnaire
Level of empowerment and engagement of patient assessed with PHE-S questionnaire
Time frame: 12 months
Therapy adherence
Will be evaluated by persistence medical treatment at 12 month follow-up as reported in the e-CRF
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UMHAT Pulmed Plovdiv-Cardiology
Plovdiv, Bulgaria
RECRUITINGAcibadem City Clinic Tokuda Hospital-Dept of Electrophysiology Clinic of Cardiology
Sofia, Bulgaria
RECRUITINGAcibadem City Clinic UMBAL Cardiovascular Center-CARDIOLOGY
Sofia, Bulgaria
RECRUITINGNational Heart Hospital-ICCU
Sofia, Bulgaria
RECRUITINGHerlev Hospital-Department of Cardiology
Herlev, Denmark
RECRUITINGNorth Denmark Regional Hospital-Department of Cardiology
Hjørring, Denmark
RECRUITING...and 40 more locations